{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:50:48Z","timestamp":1764402648274},"reference-count":32,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T00:00:00Z","timestamp":1426809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.vaccine.2015.03.011","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T01:18:15Z","timestamp":1426209495000},"page":"2030-2037","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Alternative delivery of a thermostable inactivated polio vaccine"],"prefix":"10.1016","volume":"33","author":[{"given":"Heleen","family":"Kraan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Ploemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gijsbert","family":"van de Wijdeven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Que","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"L\u00f6wik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Amorij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.03.011_bib0165","first-page":"109","article-title":"Circulating vaccine derived poliovirus and the polio eradication endgame","volume":"12","author":"Davis","year":"2012","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0170","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2012.12.076","article-title":"Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains","volume":"31","author":"Westdijk","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0175","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1016\/j.vaccine.2013.05.104","article-title":"Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults","volume":"31","author":"Soonawala","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0180","first-page":"1846","article-title":"Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats","volume":"31","author":"van der Maaden","year":"2014","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0185","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jconrel.2014.05.060","article-title":"Buccal and sublingual vaccine delivery","volume":"190","author":"Kraan","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jconrel.2011.12.039","article-title":"Towards tailored vaccine delivery: needs, challenges and perspectives","volume":"161","author":"Amorij","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0195","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/14760584.2014.883285","article-title":"Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature","volume":"13","author":"Herzog","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0200","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/17425247.2014.931936","article-title":"Intranasal formulations: promising strategy to deliver vaccines","volume":"11","author":"Riese","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0205","doi-asserted-by":"crossref","first-page":"e15043","DOI":"10.1371\/journal.pone.0015043","article-title":"Syringe free vaccination with CAF01 adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis","volume":"5","author":"Christensen","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0210","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.vaccine.2008.02.067","article-title":"Bioneedles as vaccine carriers","volume":"26","author":"Hirschberg","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jconrel.2010.06.028","article-title":"Bioneedles as alternative delivery system for hepatitis B vaccine","volume":"147","author":"Hirschberg","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0220","doi-asserted-by":"crossref","first-page":"e92806","DOI":"10.1371\/journal.pone.0092806","article-title":"Solid bioneedle-delivered influenza vaccines are highly thermostable and induce both humoral and cellular immune responses","volume":"9","author":"Soema","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0225","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejpb.2014.11.024","article-title":"Phase 1 clinical study with Bioneedles, a delivery platform for biopharmaceuticals","volume":"89","author":"van de Wijdeven","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0230","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s11095-014-1359-6","article-title":"Development of thermostable lyophilized inactivated polio vaccine","volume":"31","author":"Kraan","year":"2014","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0235","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/bit.22788","article-title":"Multivariate data analysis on historical IPV production data for better process understanding and future improvements","volume":"107","author":"Thomassen","year":"2010","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0240","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/CVI.00423-09","article-title":"Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity","volume":"17","author":"Arenas","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0245","unstructured":"van de Wijdeven G. Bioneedle Technologies Group BV, assignee. Implant containing destructurized starch. Patent WO2008\/105663. 2008 September 4."},{"key":"10.1016\/j.vaccine.2015.03.011_bib0250","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biologicals.2011.11.004","article-title":"Development of a fast ELISA for quantifying polio D-antigen in in-process samples","volume":"40","author":"Ten Have","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0255","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/BF01246393","article-title":"Some experiments on freezedrying of inactivated poliomyelitis-vaccines","volume":"12","author":"Nagel","year":"1963","journal-title":"Arch Gesamte Virusforsch"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0260","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0140-6736(55)93435-8","article-title":"The modification of poliovirus antigens by heat and ultraviolet light","volume":"269","author":"Le Bouvier","year":"1955","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1099\/0022-1317-51-1-147","article-title":"The preparation of specific immune sera against type 3 poliovirus D-antigen and C-antigen and the demonstration of two C-antigenic components in vaccine strain populations","volume":"51","author":"Minor","year":"1980","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0270","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0275","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1016\/j.bmc.2013.08.024","article-title":"Biodistribution of vaccines comprised of hydrophobically-modified poly(gamma-glutamic acid) nanoparticles and antigen proteins using fluorescence imaging","volume":"21","author":"Toita","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0280","series-title":"Vaccines","first-page":"573","article-title":"Poliovirus vaccine\u2014inactivated","author":"Vidor","year":"2013"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0285","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.vaccine.2013.11.101","article-title":"A mucosal adjuvant for the inactivated poliovirus vaccine","volume":"32","author":"Steil","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0290","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.vaccine.2010.11.043","article-title":"Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions","volume":"29","author":"Baldwin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0295","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/jmv.22030","article-title":"Chitosan as an adjuvant for poliovaccine","volume":"83","author":"Ghendon","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0300","doi-asserted-by":"crossref","first-page":"e100879","DOI":"10.1371\/journal.pone.0100879","article-title":"Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01","volume":"9","author":"Dietrich","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0305","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1016\/j.vaccine.2009.08.047","article-title":"CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus","volume":"27","author":"Yang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0310","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0264-410X(98)00409-5","article-title":"Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains","volume":"17","author":"Kersten","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0315","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/424524","article-title":"Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy","volume":"190","author":"Dragunsky","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.011_bib0320","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15002996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15002996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T07:29:16Z","timestamp":1537774156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15002996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":32,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0264410X15002996"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative delivery of a thermostable inactivated polio vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}